Invention Grant
- Patent Title: GPR40 agonists for the treatment of type II diabetes
-
Application No.: US15228031Application Date: 2016-08-04
-
Publication No.: US09908873B2Publication Date: 2018-03-06
- Inventor: Hui Huang , Sanath Meegalla , Mark R. Player
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Main IPC: C07D413/12
- IPC: C07D413/12 ; C07D333/16 ; C07D413/04 ; C07D261/12 ; C07D231/12 ; C07D333/24 ; C07D275/02 ; C07D401/12 ; C07D401/04 ; C07D409/04 ; C07D233/64 ; C07D249/06 ; C07D261/08
Abstract:
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (II) as follows: wherein R1B, R2B, R4B, WB, XB, YB, and GB, are defined herein.
Public/Granted literature
- US20170044147A1 GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES Public/Granted day:2017-02-16
Information query
